Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Lobular × entrectinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6 Neoplasm Metastasis 4 Breast Neoplasms 4 Sarcoma 3 Pancreatic Neoplasms 3 Hematologic Neoplasms 3 Brain Neoplasms 3 Thyroid Cancer, Papillary 2 Salivary Gland Neoplasms 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Leukemia, Myeloid, Acute 2 Glioma 2 Central Nervous System Neoplasms 2 Wilms Tumor 1 Uveal Melanoma 1 Thrombocytosis 1 Solid Tumors 1 Solid Tumor 1 Sarcoma, Ewing 1 Recurrence 1 Rare Tumour 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Noonan Syndrome 6 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Nephroma, Mesoblastic 1

Interventions

Letrozole 5 Radiotherapy 4 atamestane 3 Toremifene 3 Magnetic Resonance Spectroscopy 3 Chemotherapy, Adjuvant 3 Trastuzumab 2 Fulvestrant 2 Estrogen Receptor Modulators 2 Cyclophosphamide 2 Aromatase Inhibitors 2 repotrectinib 1 proto-oncogene protein c-fes-fps 1 palbociclib 1 neratinib 1 gallium 68 PSMA-11 1 fluciclovine F-18 1 entrectinib 1 Zolpidem 1 Vinorelbine 1 Venlafaxine Hydrochloride 1 Thiotepa 1 Tamoxifen 1 Sugars 1 Radiotherapy, Conformal 1 Radiation 1 Proton Therapy 1 Positron Emission Tomography Computed Tomography 1 Neoadjuvant Therapy 1 Naltrexone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04551495 2024-12-04

ROSALINE

Jules Bordet Institute

Phase 2 Active not recruiting

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡